Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Benjamin Y. Jin, Tracy E. Campbell, Lindsey M. Draper, et al.
JCI Insight (2018) Vol. 3, Iss. 8
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 585
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Asmita Pal, Rita Kundu
Frontiers in Microbiology (2020) Vol. 10
Open Access | Times Cited: 449
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Vid Leko, Steven A. Rosenberg
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 454-472
Open Access | Times Cited: 315
CD8+ T Cell Exhaustion in Cancer
Joseph S. Dolina, Natalija Budimir, Graham D. Thomas, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 309
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Smita S. Chandran, Christopher A. Klebanoff
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 127-147
Open Access | Times Cited: 255
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
Sanja Stevanović, Sarah R. Helman, John R. Wunderlich, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 5, pp. 1486-1493
Open Access | Times Cited: 240
The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
Qizhao Huang, Xia Wu, Zhiming Wang, et al.
Cell (2022) Vol. 185, Iss. 22, pp. 4049-4066.e25
Open Access | Times Cited: 239
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha Nagarsheth, Scott M. Norberg, Andrew Sinkoe, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 419-425
Open Access | Times Cited: 227
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Estelle Baulu, Célia Gardet, Nicolas Chuvin, et al.
Science Advances (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 201
Non-viral precision T cell receptor replacement for personalized cell therapy
Susan P. Foy, Kyle Jacoby, Daniela A. Bota, et al.
Nature (2022) Vol. 615, Iss. 7953, pp. 687-696
Open Access | Times Cited: 179
Systemic therapy in cervical cancer: 30 years in review
Michalis Liontos, Anastasios Kyriazoglou, Ioannis Dimitriadis, et al.
Critical Reviews in Oncology/Hematology (2019) Vol. 137, pp. 9-17
Closed Access | Times Cited: 166
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Paul Shafer, Lauren Kelly, Valentina Hoyos
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 149
Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies
Rahul Bhattacharjee, Sabya Sachi Das, Smruti Sudha Biswal, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103675-103675
Open Access | Times Cited: 117
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Qijie Zhao, Yu Jiang, Shixin Xiang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 114
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 996-1017
Open Access | Times Cited: 64
The landscape of T cell antigens for cancer immunotherapy
Aviyah Peri, Nadja Salomon, Yochai Wolf, et al.
Nature Cancer (2023) Vol. 4, Iss. 7, pp. 937-954
Closed Access | Times Cited: 60
Engineered T cell therapy for viral and non-viral epithelial cancers
Scott M. Norberg, Christian S. Hinrichs
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 58-69
Open Access | Times Cited: 46
TCR engineered T cells for solid tumor immunotherapy
Yikai Zhang, Zhipeng Liu, Wei Wei, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 42
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer
Cem Sievers, Marco Craveiro, Jay Friedman, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 887-902.e5
Open Access | Times Cited: 30
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Jianping Li, Zhiwen Xiao, Donghui Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Targeted Gene Delivery Therapies for Cervical Cancer
Ángela Ayén, Yaiza Jiménez Martínez, Houría Boulaiz
Cancers (2020) Vol. 12, Iss. 5, pp. 1301-1301
Open Access | Times Cited: 51
Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives
Ying Tang, Anne X.J. Zhang, Guangyu Chen, et al.
Molecular Therapy — Oncolytics (2021) Vol. 22, pp. 410-430
Open Access | Times Cited: 50
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
Xuqing Zhang, Mengyao Luo, Shamael R. Dastagir, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 48
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Katarzyna Starska
Cancers (2023) Vol. 15, Iss. 6, pp. 1642-1642
Open Access | Times Cited: 21
T cell immunotherapy for cervical cancer: challenges and opportunities
Lingfeng Yu, Gong Lanqing, Ziyu Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top